Search results
Showing 2656 to 2670 of 8937 results
Tildrakizumab for treating active psoriatic arthritis [TSID12218]
Awaiting development Reference number: GID-TA11807 Expected publication date: TBC
In development Reference number: GID-TA11508 Expected publication date: 29 July 2026
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]
Awaiting development Reference number: GID-TA11982 Expected publication date: TBC
Obinutuzumab for treating primary membranous nephropathy [ID6751]
Awaiting development Reference number: GID-TA11983 Expected publication date: TBC
In development Reference number: GID-TA11963 Expected publication date: TBC
Digital technologies to support self-management of asthma: early value assessment
In development Reference number: GID-HTE10063 Expected publication date: 30 April 2026
In development Reference number: GID-IPG10441 Expected publication date: TBC
Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Summary of the evidence on antimicrobial prescribing: delafloxacin
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults